Globus Medical, Inc.
GMED
Rangering i aksjer
#1985
Globus Medical, Inc. is a global medical technology company dedicated to... Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
Aksjekurs
$79.05
Sist synkronisert: 2026-10-20
Markedsverdi
$10.61B
Endring (1 dag)
4.29%
Endring (1 år)
26.02%
Land
US
Handel Globus Medical, Inc. (GMED)
Kategori
Healthcare
P/E-forhold for Globus Medical, Inc. (GMED)
P/E-forhold per October 2026 TTM: 19.22
Ifølge Globus Medical, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 19.22. Ved slutten av 2023 hadde selskapet en P/E på 49.05.
P/E-forholdshistorikk for Globus Medical, Inc. fra 2009 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 19.22 | -82.37% |
| 2024 | 109.01 | 122.25% |
| 2023 | 49.05 | 25.00% |
| 2022 | 39.24 | -19.51% |
| 2021 | 48.75 | -22.44% |
| 2020 | 62.86 | 67.12% |
| 2019 | 37.61 | 38.93% |
| 2018 | 27.07 | -26.52% |
| 2017 | 36.85 | 62.02% |
| 2016 | 22.74 | -2.99% |
| 2015 | 23.44 | -3.19% |
| 2014 | 24.22 | -11.12% |
| 2013 | 27.25 | 114.03% |
| 2012 | 12.73 | -21.14% |
| 2011 | 16.14 | -10.41% |
| 2010 | 18.02 | -26.17% |
| 2009 | 24.41 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 33.11 | 72.25% |
US
|
|
| 21.39 | 11.27% |
IE
|
|
| 28.94 | 50.58% |
US
|
|
| 17.34 | -9.80% |
US
|
|
| - | - |
DE
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.